Although no statistical significance was identified, the new P2Y 12 receptor inhibitor, ticagrelor, showed a trend toward achieving the greatest beneficial effect compared to other regimes, which gives it the highest probability of being the optimal therapy.
← all excerpts
Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis.
1
—
—